News | July 17, 2023
Evonik and Heraeus cooperate to expand the range of services for highly potent API
Evonik specializes in mid- to large-scale, later clinical phase HPAPIs
Evonik specializes in mid- to large-scale, later clinical phase HPAPIs
Adding 20,000 liters of installed biologics drug substance manufacturing capacity
The transaction represents an enterprise value of €275 million, an estimated 2023 EV/EBITDA multiple of 18x
Exothera will manufacture Meissa’s MV-012-968 vaccine candidate under CGMP regulations to supply Phase 2 clinical trials
Under the terms of the collaboration, Vertex and Lonza will partner in the process development and scale-up for the manufacturing of the product portfolio and co-invest to build a dedicated new facility in Portsmouth, New Hampshire (US)
As Caeregen’s CDMO partner for CTR-107, Wacker Biotech will produce drug substance at its site in Halle, Germany, and complete clinical trial drug product production at its site in Amsterdam, the Netherlands
Sajjan India Limited is looking for expansion, both organically and through acquisitions, to achieve the planned growth
Acquisition will further strengthen Lonza’s bioconjugates offering through the integration of the industry-leading proprietary Synaffix technology platform and R&D capabilities, including payload and site-specific linker technology
Concept Medical’s manufacturing arm has reduced its carbon footprint via in-house efficiency improvement programmes & green infrastructure
Cooperative agreement with U.S. Government to advance U.S. biopharma industry and ensure pandemic preparedness
Subscribe To Our Newsletter & Stay Updated
